Figures
Figure 1: The serum levels (mean, 95% confidence intervals and individual symbols) of anti-glutamic acid decarboxylase autoantibodies (Anti-GAD) in anti-GAD positive (> 0.90 kU/L) Common variable immunodeficiency patients (CVID+) compared to newly diagnosed patients with Type 1 diabetes (T1D).
Figure 2: The serum concentration (mean, 95% confidence intervals and individual symbols) of C-peptide (C-p) in anti-GAD negative (CVID-) and positive Common variable immunodeficiency patients (CVID+) and at baseline (BSL), end-of-study (EOS) visits compared to newly diagnosed patients with Type 1 diabetes (T1D) are displayed, upper (1470 pmol/L) and lower (370 pmol/L) reference limits indicated by bold gridlines.
Figure 3: The serum levels (mean, 95% confidence intervals and individual symbols) of anti-thyroid peroxidase autoantibodies (Anti-TPO) in anti-TPO positive (> 0.60 kU/L) Common variable immunodeficiency patients (CVID+) compared to newly diagnosed patients with Autoimmune thyroiditis (AIT).
Supplementary Figure 4: The concentration of of anti-glutamic acid decarboxylase (anti-GAD) autoantibodies (mean, 95% confidence intervals and individual symbols) in different solutions for immunoglobulin replacement therapy (10% solution for intravenous use IVIG-I and IVIG II, 16.5% and 20% solutions for subcutaneous use SCIG-16.5 and SCIG-20), statistically significant differences (p ≤0.0001), upper reference limit (0.9 kU/L) indicated by bold gridline.
Supplementary Figure 5: The concentration of anti-thyroid peroxidase autoantibodies (Anti-TPO) autoantibodies (mean, 95% confidence intervals and individual symbols) in different solutions for immunoglobulin replacement therapy (10% solution for intravenous use IVIG-I and IVIG II, 16.5% and 20% solutions for subcutaneous use SCIG-16.5 and SCIG-20), differences statistically non-significant (p= 0.064), upper reference limit (60.0 kU/L) indicated by bold gridline.